The mean difference (MD) and 95% confidence intervals (CIs) were used to assess the effects of SGLT-2 inhibitors on liver fibrosis indicators, including the Fib-4 index, NAFLD fibrosis score (NFS), liver stiffness measurement (LSM), controlled attenuation parameter (CAP), and serum type 4 collagen 7s levels.<h4>Results</h4>A total of 16 RCTs involving 11,300 subjects were included. This evidence concerns the gene SLC5A2 and Hepatic fibrosis.